NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
Brain metastases are one of the most severe complications of melanoma, the most aggressive type of skin cancer. Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback